Moderna and Merck mRNA Cancer Vaccine Prevents Melanoma Recurrence

Moderna and Merck announced on Wednesday, August 19, 2026, that a 1,137-volunteer trial demonstrated their personalized mRNA cancer vaccine, intismeran autogene, reduced the risk of surgically removed melanoma returning or spreading.

The treatment combines up to nine doses of Merck's immunotherapy drug Keytruda with nine doses of a customized mRNA vaccine designed to train the immune system to target individual tumor mutations without causing new side effects.

Dr. Ryan Sullivan, director of the Center for Melanoma at Mass General Brigham Cancer Institute, highlighted the broad potential of the positive study for the field.

"It is a big deal for the field in general," said Dr. Ryan Sullivan, director of the Center for Melanoma at Mass General Brigham Cancer Institute. "With this positive study, there is hope (and likely investment to follow) that these approaches may change the way we treat cancer more broadly."

Dr. Julie Gralow, chief medical officer of the American Society of Clinical Oncology, praised the breakthrough as a major milestone for mRNA applications in oncology.

"a monumental leap forward," said Dr. Julie Gralow, chief medical officer of the American Society of Clinical Oncology.

Beyond melanoma, Moderna and Merck are testing the combination in trials for lung, bladder, kidney, pancreatic, and stomach cancers, while rival firms Roche and BioNTech test similar mRNA treatments for colon and pancreatic cancers.

"We should be hearing results from multiple studies over the next few years and there's every reason to hope now, with this news, that many of them will be positive," said Dr. Robert Vonderheide, director of Penn Medicine's Abramson Cancer Center and president-elect of the American Association for Cancer Research.

Initial skepticism surrounded the program, with top executives previously doubting its potential before mid-stage and late-stage trial data confirmed significant efficacy.

"None of us believed it," said Stephen Hoge, President of Moderna.

Previous mid-stage trial data presented in June showed the vaccine cut recurrence risk by half and reduced distant spread by 59 percent compared to Keytruda alone.

"What we saw in the (mid-stage trial) were the kinds of reactions people were having when they got a flu or COVID shot or any other vaccine," said Stephen Hoge, President of Moderna.

Specialists noted that adding the vaccine provides a critical extra benefit for high-risk patients evaluating post-surgery options.

"may change that math," said Dr. Elizabeth Buchbinder, melanoma specialist at the Mass General Brigham Cancer Institute.

The underlying high mutation rate of melanoma makes it an ideal initial target, though researchers anticipate widespread application across other tumor types.

"We'll see, but it's definitely an area that is going to be exploding, especially with these results coming out," said Dr. Elizabeth Buchbinder, melanoma specialist at the Mass General Brigham Cancer Institute.

Moderna expects thousands of melanoma patients could benefit within the first few years of regulatory approval as ongoing trials continue to track long-term overall survival rates.